

INTERACTION OF TEMAZEPAM WITH CERTAIN MACROMOLECULES
VIII-FORMULATION OF TABLETS CONTAINING TEMAZEPAM
SOLID DISPERSIONS

Aly A. Abdel Rahman*, A.E. Aboutaleb*, B.A. Mulley** and S.M. Ahmed*

Dept. of Industrial Pharmacy, Faculty of Pharmacy, Assiut University,
Egypt* and School of Pharmacy, Bradford University, England**

ABSTRACT

Temazepam-polyethylene glycol 6000 (PEG 6000) coprecipitates has been formulated as tablets using direct compression technique. This coprecipitation was chosen as it exhibited an optimum drug release characteristic and could be easily handled and pulverized.

Differential scanning calorimeter (DSC) was utilized to check the compatibility of temazepam with Avicel pH 101 and magnesium stearate as well as the effect of ageing on the formulated coprecipitates, at different storage conditions. It was concluded that the drug is compatible with those tablet excipients, and no detectable changes resulted from ageing.

Compression of the formula containing 1:3 w/w temazepam-PEG 6000 coprecipitates produced good quality tablets having rapid disintegration and rapid dissolution rates. Tablets of 1:7 w/w ratio were highly compact and having a lower disintegration and a lower dissolution rates. This shows the importance of optimizing the formulations by finding out the correct quantity of excipients to maintain better dissolution properties.

The results obtained indicated that 1:3 w/w temazepam-PEG 6000 coprecipitates retains its higher dissolution when compressed as tablets. Additionally, this tablet formulation helped to provide temazepam in a high quality dosage form.

INTRODUCTION

The formulation of solid dispersions with various pharmacologically inert carriers is one of the techniques that potentially enhance the dissolution rate and extent of absorption of hydrophobic drugs. Ultimately, solid dispersions required formulation into dosage forms, either tablets or capsules. For the former, wet granulation techniques are unacceptable since aqueous

fluids would break down the dispersion destroying its fast release characteristics¹. Solid dispersions may often be tacky and unhandable², but when they are easy to pulverize direct compression, double compression, or encapsulation technique may be used. Direct compression with or without direct compression aids has been accomplished successfully for dispersions including certain drugs³⁻⁶.

Temazepam is marketed as soft gelatin capsules containing solution of the drug in polyethylene glycol. From the technological point of view, the gelatin capsule is difficult to be manufactured and stored. In addition to the problem of leakage of the contents which seems to be a common fault with all temazepam capsules in the market, including the branded versions⁷, Maguire⁸ stated that the supply of temazepam formulated in soft gelatin capsules, however, is still presenting some problems. Many patients prefer one particular brand and refuse the others of different manufacturers because they observed inadequate or adverse clinical activity when they received a change. Maguire declared that this was not purely psychological, but there might be a fundamental difference in the pharmacokinetics of the drug. In a recent review, Ford¹ mentioned many additional advantages for solid dispersions, that provide scope for the continued interest in solid dispersions. Of these advantages, maintaining the drug in a bioavailable form⁹, dosage reduction¹⁰ and cleaner manufacturing conditions¹¹.

The aim of the present work is to develop a convenient dosage form of temazepam prepared in solid dispersions. As a result of the intensive studies done on solid dispersion of this drug with some hydrophilic carriers¹², the best carrier, the optimum composition and the best method for the preparation of temazepam solid dispersions were chosen as a basis for the work done in this article. Based on these observations, temazepam-PEG 6000 coprecipitates were formulated as tablets.

*Interaction of Temazepam With Certain Macromolecules
VIII-Formulation of Tablets Containing Temazepam
Solid Dispersions*

EXPERIMENTAL

Materials and Methods :

Temazepam (Fabrica Italiana Sintetici, Laboratorio, Controllo Alte Montecchio (vicenzo), Italy).

Plyethylene glycol 6000 (PEG 6000), (B.D.H. chemicals Ltd, Poole, England).

Polyoxyethylene (40) stearate (Myrj 52), (Atlas Chemical Industries, Ltd, England).

Microcrystalline cellulose (Avicel pH 101), (F.M.C. International Food and Pharmaceutical Products, Ireland).

Magnesium stearate (B.D.H. Chemicals Ltd, Poole, England).

Apparatus :

Dissolution apparatus (Erweka-apparatebau, G.m.b.H., West Germany). CE 292 digital ultraviolet spectrophotometer C-CIL (Instrum-CIL (Instrum-NTS, Cambridge, England).

Multipen-recorder (Rikadenki Mitsni Electronics Ltd, England). Shaking water bath (Grant instruments, Cambridge Ltd, England). Dupont Differential Scanning Calorimeter (DSC) connected to Dupont 1091 Disc momery (Dupont Co., Analytical instruments Division, Willimington, USA).

Hp 8451 A Diode array-spectrophotometer, 98155 A with keyboard and 7470 A plotter (Hewlett packard, USA).

Single punch tablet machine and tablet disintegration test unit(Manesty Machines, Ltd., Liverpool, England).

Tablet hardness tester, (Heberlein & Co. A.G., Switzerland). Screw gauge micrometer, (Mercer 130/3, England).

Roche friabilator, (J.E.L., Ludwigshafen, Rhein. W. Germany).

Methods :

Assay of Temazepam: Ultraviolet spectrophotometric method was adopted for temazepam determination alone or in various test preparations using a computerized HP 8451 Diode Array spectrophotometer. The drug absorbance was determined at 232 nm¹². The concentrations of temazepam were determined from the calibration curve which followed Beer's law.

Preparation of Temazepam-PEG 6000 Coprecipitates :

1:1, 1:3 and 1:7 Temazepam-PEG 6000 solid dispersions as well as controls were prepared by both solvent and fusion methods^{12,13}.

Characterization of the Produced Coprecipitates :A- Ultraviolet Spectrophotometric Studies :

The U.V. studies of the pure and the processed temazepam (5 ug/ml) were carried out¹³. The presence of the carrier did not interfere with the spectrophotometric assay of the drug ,Fig. 1.

B- Thin Layer Chromatographic Investigation :

The dispersions prepared were analyzed by TLC to check the chemical stability of temazepam during processing, as mentioned before¹³. It was found that the processed Temazepam was stable and no signs of degradation appeared.

C- Differential Scanning Calorimetric Studies :

DSC of the freshly prepared coprecipitates as well as the stored ones were carried out^{12,13} in order to determine the transition temperature and the heats of fusion.

Tablet Formulation Compatibility of Temazepam with the Suggested Tablet Excipients :

DSC technique was used to check the compatibility of temazepam with Avicel PH 101 and magnesium stearate. Thermograms for individual substances and for 1:1 w/w physical mixtures of the drug with either Avicel PH 101 or magnesium stearate were plotted. Apparatus and procedures used are described before^{12,13}.

Tablet Compression :

Three solid dispersion formulae were chosen from detailed studies based on the dissolution work done¹² and characteristics of the solid dispersions investigated¹².

*Interaction of Temazepam With Certain Macromolecules
VIII-Formulation of Tablets Containing Temazepam
Solid Dispersions*

Each tablet was formulated to contain 10 mg temazepam.

Formula A : (control formula)

Temazepam powder (45-200 U)	10 mg
Magnesium stearate	1 mg
Avicel PH 101 to	200 mg

Formula B :

1:3 w/w Temazepam -PEG 6000 coprecipitates	80 mg
Magnesium stearate	1 mg
Avicel PH 101 to	200 mg

Formula C :

1:7 w/w Temazepam - PEG coprecipitates	80 mg
Magnesium stearate	1 mg
Avicel PH 101 to	200 mg

Formula D :

1:3 temazepam - Myrj 52 coprecipitates	40 mg
Magnesium, stearate	1 mg
Avicel PH 101 to	200 mg

The ingredients of each formula, except magnesium stearate, were blended in a glass jar for 25 minutes. Magnesium stearate, was sieved in and blended for an additional 5 minutes. A Manesty single punch tablet machine with concave surface was used to compress the tablets. Compression force was adjusted to give tablets of suitable hardness.

Many attempts were done to compress formula D using 1:3 w/w temazepam-Myrj 52 coprecipitates, this proved to be impossible due to cracking of the tablets produced.

Properties of the Compressed Tablets :

- a) Tablet Dimensions : The height and diameter of each tablet were measured using a screw gauge micrometer. Results given are the average of ten tablet determinations.
- b) Tablet Hardness : The tablet crushing strengths (kg) of eight tablets were determined using the Heberlein hardness tester.
- c) Disintegration time : The disintegration of the tablets was studied at $37 \pm 0.5^\circ\text{C}$ using the disintegration test apparatus of the British

pharmacopoeia with the disc. Values are the average of two determinations.

- d) Uniformity of Drug Content : Five tablets were selected randomly from each batch. Each tablet was ground in a mortar, washed quantitatively into a volumetric flask with absolute ethanol. The contents of the flask were shaken well for 30 minutes, filtered and 2.5 ml of the filtrate was diluted to 50 ml with distilled water. The diluted aqueous solution was assayed for its temazepam contents.
- f) Dissolution Rates : The dissolution rates of the tablets was determined using Erweka dissolution apparatus. The dissolution medium was 900 ml distilled water of 37°C. The dissolution medium was automatically measured for its drug content in a continuous spectrophotometric flow system. A filter tip was fixed to the inlet tube, also, inlet and exit of the tubes were fixed. Agitation of the dissolution medium was accomplished by a stirring paddle at a rate of 100 r.p.m. A cylindrical stainless steel basket was fixed to the end of the rotating shaft instead of the blade, One tablet was placed in the basket and the dissolution profile of the drug was recorded and drawn at 232 nm for 30 minutes.

RESULTS AND DISCUSSION

Since it was believed that incorporation of solid dispersions into tablets provides a dosage form with fast release properties relative to test tablets of untreated drug, a trial was made to apply this technique to prepare good quality tablets of temazepam, to evaluate the effects of tableting on the drug release from solid dispersions.

The selection of the most suitable dispersion carrier, drug: carrier ratio and the best method of preparing the solid dispersions for the construction of the tablet formulae were based on the data obtained from the dissolution rate studies.¹² Those preparations provided solid dispersions having the highest dissolution rates were selected.

Interaction of Temazepam With Certain Macromolecules
VIII-Formulation of Tablets Containing Temazepam
Solid Dispersions

Direct compression technique was chosen to manufacture solid dispersion tablets, as it is advantageous in terms of low cost, simplicity and product stability^{14,15}. Microcrystalline cellulose was used as a directly compressible vehicle for the preparation of temazepam solid dispersion tablets. Magnesium stearate was selected as a lubricant¹⁶.

Compatibility of Temazepam with the Suggested Tablet Excipients:

Differential scanning calorimetry was utilized to check the compatibility of temazepam with the suggested tablet excipients¹⁷⁻²¹.

The DSC thermogram of temazepam (Trace 1 of Fig. 2) showed a melting endotherm at 162°C, with a heat of fusion (ΔH_f) of 27.5 kJ/mole. The DSC thermogram of Avicel PH 101 (Trace 2 of Fig. 2) showed no characteristic features at the temperature of interest (35-175°C).

As a rule, if the DSC thermogram of an equal mixture of the drug and the excipient reflects the characteristic features of the thermograms of each component, it could be concluded that there is no interaction between them, i.e., there is no physicochemical incompatibility, and vice versa¹⁷. It was found that the DSC thermogram of 1:1 w/w mixture of temazepam-Avicel PH 101 (Trace 3 of Fig. 2) showed the combined features characteristics of the thermograms of each component. The heat of fusion, kJ/mole, was found to be quantitatively identical to the predicted value of temazepam (27.5 k_J/mole) indicating no incompatibility under these conditions.

DSC thermograms of magnesium stearate (Trace 2 of Fig. 3) showed two broadened transitions at about 72°C and 100°C respectively. DSC thermogram of 1:1 w/w temazepam -magnesium stearate (Trace 3 of Fig. 3) combined the features characteristic of the thermograms of each component, but with a slight broadening of the temazepam melting endotherm. The heat of fusion of temazepam (27.5 K_J/mole) was found to be quantitatively identical to the predicted value indicating no incompatibility between temazepam and magnesium stearate under the condition of the test.

In a similar manner, El-Shattawy¹⁹ has found that anhydrous ampicillin was compatible with Avicel PH 101, Avicel PH 105, Elcema F 150, STA-RX 1500 and Cab-O-Sil, while incompatible with sorbital and dicalcium phosphate dihydrate.

Therefore, DSC can distinguish between those excipients unlikely to cause a problem and those that may cause troubles and thereby a more rational approach to early formulation designs could be established. Although it can be conclusively studied that an incompatibility interaction will occur during storage at room temperature, this method can give an early warning of such a possibility¹².

In order to predict any thermal and crystalline changes that may happen on ageing of temazepam coprecipitates intended to be formulated into the tablets under investigation, DSC of some of the stored samples were compared with those of fresh ones, Fig. 4 & 5. Fig. 4, shows the effect of ageing on temazepam stored at 37 and 45°C. It is obvious that there is no change in the shape of the thermogram. Only a slight increase in melting point about (1-2°C) was observed on ageing. This increase is possibly due to a very slight increase in the crystal size or due to the trapped air.

Fig. 5 shows the effect of storage conditions (20°C/75% R.H, 37 and 45°C) on 1:3 w/w temazepam -PEG 6000 coprecipitates. It is obvious that the fresh and the aged samples are very similar, showing one melting endotherm of PEG 6000 and in both cases disappearance of the characteristic melting endotherm of temazepam. This clearly indicate that temazepam is still present in the stored coprecipitates as very fine crystallites or the amorphous form. Thus ageing of the formulated coprecipitates did not produce any detectable changes.

Interaction of Temazepam With Certain Macromolecules
VIII-Formulation of Tablets Containing Temazepam
Solid Dispersions

Properties of Temazepam Tablets :

Tablets prepared from temazepam and its PEG 6000 dispersions by the direct compression technique have a white and shiny appearance. Table 1 shows the properties of the prepared tablets. Generally, these results indicate the possibility of producing directly compressed temazepam tablets having satisfactory properties. Although it is believed that there is a great chance of drug content per tablet variation, it was found that temazepam tablets prepared using this technique have reasonable uniformity of drug content.

As 1:7 w/w temazepam-PEG 6000 coprecipitate in powder form showed the highest dissolution rate¹², it was expected that the drug release rate from formulated tablets would be superior. Actually, this is not the case as those tablets showed the lowest dissolution, Table 1. Comparison of the T 50%'s and the relative dissolution rates of the prepared tablets gave the rank order for the dissolution of test tablets :1:3 w/w coprecipitate > untreated temazepam > 1:7 w/w coprecipitate tablets. Upon further examination of the results in Table 1, it is clear that the poor dissolution of the tablets prepared from 1:7 w/w temazepam-PEG 6000 coprecipitate was due to the poor disintegration properties of the tablet. This could be noticed in tablets containing higher proportion of PEG 6000 than those of 1:3 w/w coprecipitate tablets. It appears that high PEG 6000 content is undesirable during direct compression of solid dispersions because it produces highly compacted and tacky tablets resulting in delaying disintegration. Ford²² has concluded that tablets containing high PEG 6000 levels were hard and capping occurred during compression. The present results indicate that direct compression of 1:3 w/w temazepam-PEG 6000 coprecipitate (Formula B) produces tablets having very rapid disintegration and a high dissolution rate. This shows the importance of optimizing formulations by finding the correct quantity of excipients to maintain good dissolution properties without tackiness.

Fig. 6 shows the marked superiority in dissolution rate of the 1:3 w/w temazepam - PEG 6000 coprecipitate tablets over the drug alone and 1:7 w/w temazepam -PEG 6000 coprecipitates in tablets. This effect may be partially due to the rapide disintegration of the former tablets when they become in contact with the dissolution medium. This fact, beside the other mechanisms which lead to a higher drug release from its coprecipitate may account for the observed higher dissolution rate for the tablets containing this ratio of the coprecipitating agent.

Interaction of Temazepam With Certain Macromolecules
VIII-Formulation of Tablets Containing Temazepam
Solid Dispersions




FIG. 1: UV-ABSORPTION SPECTRA OF TEMAZEPAM (1), 1:1 W/W TEMAZEPAM-PEG COPRECIPITATE (2) AND 1:7 W/W TEMAZEPAM-PEG 6000 COPRECIPITATE (3).




FIG. 2: DSC THERMOGRAMS OF TEMAZEPAM (1), AVICEL PH 101(2) and 1:1 W/W TEMAZEPAM-AVICEL PH 101 MIXTURE.




FIG. 3: DSC THERMOGRAMS OF TEMAZEPAM (1), MAGNESIUM STEARATE (2) and 1:1 W/W TEMAZEPAM-MAGNESIUM STEARATE MIXTURE.

*Interaction of Temazepam with Certain Macromolecules
VIII-Formulation of Tablets Containing Temazepam
Solid Dispersions.*




Fig. 4. The Effect of Ageing on DSC Thermogram of Temazepam of Temazepam Stored At Various Conditions.

Key; A, Fresh Sample

B, Sample Stored at 37°C.

C, Sample Stored at 45°C.




Fig. 5: The Effect of Ageing on DSC Thermograms of 1:3 w/w Temazepam-PEG 6000 Coprecipitate Stored at Various Conditions.

Key : A, Fresh Sample

B, Sample Stored at 20°C. -75 % R.H. for 8 months

C, Sample Stored at 37°C for 8 months.

D, Sample Stored at 45°C for 8 months.




FIG (6) DISSOLUTION PROFILES OF TEMAZEPAM TABLETES (CONTROL) AND PEG 6000 COPRECIPTATES IN TABLET FORM (MEAN OF 4 DETERMINATIONS).

Interaction of Temazepam With Certain Macromolecules
VIII-Formulation of Tablets Containing Temazepam
Solid Dispersions.

Table 1 : Physical Properties of Tablets Prepared by Direct Compression of Temazepam Solid Dispersions.

Formulation	Dimensions (mm)		Hardness (Kg)	Friability (%)	Disintegration Time (seconds)	Dissolution Parameters T _{50%} (minutes)		
	Thickness	diameter				R.D.R. (min.) 10	20	
Temazepam alone in tablets	4.184	8.775	5.3±0.6	0.680	36	12.10	1	1
1:3 Temazepam-PEG 6000 coprecipitate tablets	4.13	8.778	5.8±0.4	0.241	30	3.60	2.50	1.43
1:7 Temazepam-PEG 6000 coprecipitate tablets	3.66	8.775	5.3±0.6	-----	570	13.50	0.58	0.61

REFERENCES

- 1- J.L. Ford, *Pharm, Acta Helv.*, 61, 69 (1996).
- 2- W.I. Chiou and S. Niazi, *J. Pharm. Sci.*, 60, 1333 (1971).
- 3- H.M. El-Banna, A.G. Eshra, and Y., Hammouda, *Pharmazie*, 32, 511 (1977).
- 4- J.L. Ford and M.H., Rubinstein, *Int.J. Pharm;* 8, 311 (1981).
- 5- J.L. Ford., *Pharm., Pharm. Acta Helv.*, 58, 101 (1983).
- 6- W.R., Ravis, and C.Y. Chen, *J. Pharm. Sci.*, 70, 1353 (1981).
- 7- .W. Hemingway., *Private communication*, Approved prescription services Ltd, England, (1986).
- 8- T. Maguire, *Pharm. J.*, 235, 822 (1986).
- 9- H.G. Schroeder, A. Dakkuri, and P.P. de Luca, *Cancer Treat Rev.*, 67, 350 (1978).
- 10- P.V. Dankwert, *Ind. Eng. Chem.* 43, 1460 (1951).
- 11- S.F. Walker, J.A. Canley, K. Bedford and T. Evans, *J. Pharm. Pharmacol.*, 32, 398 (1980).
- 12- S.M. Ahmed., *Ph.D. Thesis*, Assiut University, 1987, Chapter 1.
- 13- Abdel Rahman A.A., Aboutaleb, A.E. and Mulley, B.A.; *Bull. Pharm. Sci. Assiut University*, in the press.
- 14- S.C. Rao; *Indian Drugs*, 16, 69 (1978).
- 15- E. Mendell, *Manuf. Chem. Aerosol News*, 48, 43 (1972).
- 16- M.O. Ahmed, *M.SC. Thesis*, Assiut University, 1986.
- 17- A.A. Dooren, *Drug Devel. Indust. Pharmacy*, 9, 43 (1983).
- 18- A. Smith, *Anal. Proc.* 559 (1982).
- 19- H.H. El-Shattawy, *Drug Devel. Indust. Pharmacy*, 10, 491 (1984).
- 20- H.H. El-Shattawy, G.E. Peck and D.O. Kildsig, *ibid*, 8, 429 (1982).
- 21- K.C. Lee, and J. A. Hersey; *J. Pharm. Pharmacol.*, 29, 515 (1977).
- 22- J.L. Ford, *Ph.D. Thesis*, Liverpool, Polytechnic, 1980.

تفاعلات التيمازيبام مع جزئيات كبيرة معينه :
 ٨ - صياغة أقراص تحتوى على المتراسبات الملمبة للتيمازيبام

على عبد الظاهر عبد الرحمن ، أحمد السيد أبوطالب ، براين أرثر مللى ، سيد محمد أحمد
 قسم الصيدلة الصناعية - كلية الصيدلة - جامعة أسيوط - مصر
 كلية الصيدلة - جامعة براد فورد - انجلترا .

صيغت متراسبات التيمازيبام مع عديد ايثلين جليكول ٦٠٠٠ كأقراص باستخدام
 الكبس المباشر .

ولقد اختير هذا المتراسب لأنه أعطى أعلى معدل اتاحة كما أنه من السهل
 تناوله وطحنه .

ولقد استخدم المسح التفاضلى السعري وذلك لاختبار توافق التيمازيبام
 مع الافسيل ١٠١ وسترات الماغنسيوم وكذلك تأثير التخزين على المتراسبات فى
 ظروف تخزين مختلفة . ولقد استنتج أن التيمازيبام متوافق مع المواد المذكورة
 والمستخدمه كمواغات للأقراص . ولم تحدث كذلك أية تغييرات ملموسة بالتخزين .

ولقد نتجت اقراص لها معدل اتاحة وتفتت سريع وذلك عند كبس المتراسبات
 التى تحتوى ١ : ٣ وزنا على وزن من التيمازيبام : عديد ايثلين جليكول ٦٠٠٠ .

أما الاقراص التى تحتوى على نسبة ١ : ٧ فقد انتجت أقراصا عالية
 التماسك ولها معدل تفتت واتاحة أقل .

وهذا يوضح أهمية نسبة المواغات فى تحقيق اتاحة أعلى للأقراص المحضرة

 received in 18/9/1989 & accepted in 10/2/1990